SCIAD United Kingdom

Sciad Communications is a leading marketing and PR consultancy working in Health, Science and Tech.Our aim is to make our clients more successful. By integrating Brand, PR and Digital Marketing we build reputations, accelerate growth and attract investment. We have an excellent track record in developing communications programmes for our clients, helping them to stay ahead of their competitors and become market leaders.

membership
Organisation type
Ms Deborah Cockerill
LinkedIn logo Managing Partner and Co-Founder 

Scottish Development International United Kingdom

Scottish Development International is a government-funded organisation which provides access to key Scottish product and service companies in the life sciences, together with research and clinical expertise from Scottish Universities and Research Institutes and financial support programs to support your development.

Scotland’s life sciences sector consists of over 650 organisations employing over 32,500 people and is one of the world's leading centres for stem cell research and regenerative medicine. Scotland has built a reputation as one of Europe's leading locations for the development of new tools and technologies, as well as the clinical assessment of new cell-based therapies. These strengths are based on the connectivity of the translational, clinical, analytical and regulatory support mechanisms.

Mrs Emily Lekkas
LinkedIn logo International Senior Executive 
Ms Katharina Kraehahn
LinkedIn logo Senior Business Development Executive 

Seda Pharmaceutical Development Services United Kingdom

The integrated Pharmaceutical Development and Clinical Pharmacology Service that maximises value build.

We are based at Cheadle Royal Business Park, a centre of scientific excellence in the North of England.

By choosing Seda you can rest assured you are in safe hands. Our team have delivered high quality products, processes and regulatory submissions leading to the approval and launch of several successful medicines. We have practiced across therapeutic areas and have extensive experience in the development of Oncology drugs, including those with ‘breakthrough’ status.

Seda are pioneers of novel approaches to accelerate projects that can save you money and create better value. Our team of experts have deep scientific experience across a broad range of disciplines and stages of development, from discovery to launch.

Strategy > Design > Data > Interpretation > Execution

  • Consultancy
  • Physicochemical characterisation and preformulation studies
  • Solid form selection including polymorphs, salts and co-crystals
  • Preclinical safety study formulation development for challenging molecules
  • First-time-in-clinic and later phase / commercial formulation development
  • Enabling formulations and specialist drug delivery technology selection
  • Preclinical DMPK
  • Clinical pharmacokinetics and drug absorption including modeling
  • Due diligence, competitor analysis and technology opportunity assessments
  • Scientific leadership: academic - industry collaborations; training and mentoring; scientific advisory boards
 

Routes of administration and technology areas we cover:

Oral

  • Immediate release
  • Modified release
  • Oral poorly solubles
 

Standard Injectables 

Complex Injectables

  • Poorly soluble IV
  • Depot
  • Targeted

Nasal and Inhaled

Website:
www.sedapds.com
membership
Organisation type
Dr Paul Dickinson
Dr Paul Dickinson
LinkedIn logo Director 
Dr Marcel de Matas
Dr Marcel de Matas
LinkedIn logo Director 

Selcia United Kingdom

Selcia is a leading global CRO specialising in 14C GMP radiolabelled API for clinical trials and in 14C custom radiolabelling for DMPK, dermal penetration and environmental fate studies.

Selcia offers the full range of drug discovery services; integrated drug discovery, assay development, medicinal chemistry and ADME. With specialist expertise in macrocycles, natural products and their simplification and optimisation for drug use. Selcia has a unique peptidyl prolyl isomerase (PPIase) inhibitor screening platform.

To support regulatory submissions, Selcia offers GLP analysis; including GLP NMR (500MHz), mass spectrometry, HPLC (analytical and preparative) and specialised purification capabilities from analytical (µg) to multi-100g scale.

Website:
www.selcia.com
Organisation type
Mr Dave Roberts
BD Director Radiochemistry 

Seven Bridges United Kingdom

Seven Bridges is the biomedical data analysis company accelerating breakthroughs in genomics research for cancer, drug development and precision medicine. The scalable, cloud-based Seven Bridges Platform empowers rapid, collaborative analysis of millions of genomes in concert with other forms of biomedical data. Thousands of researchers in government, biotech, pharmaceutical and academic labs use Seven Bridges, including three of the largest genomics projects in the world: U.S. National Cancer Institute’s Cancer Genomics Cloud pilot, the Million Veteran Program and Genomics England’s 100,000 Genomes Project. As the NIH’s only commercial Trusted Partner, Seven Bridges authenticates and authorizes access to one of the world’s largest cancer genomics dataset. The company has offices in Cambridge, Mass.; Belgrade; London and San Francisco.

Mr Michael Reynolds
LinkedIn logo Senior Account Director 

Sharp Clinical Services United Kingdom

Sharp Packaging Services works across the world to create unique commercial and clinical packaging solutions for the pharmaceutical and biotechnology industry.

We are made up of two dynamic international divisions, Sharp Packaging Solutions and Sharp Clinical Services. Together our 1,600-strong team works from state-of-the-art facilities in the United States, United Kingdom, Belgium and the Netherlands.

We’ve built an exceptional global reputation for the design, serialisation and production of innovative, cost-effective compliance packaging for even the most complex products.

Our extensive range includes blister packs, bottles, pouches and stick packs, but our expertise goes far beyond, enabling us to support your product through every stage of design, development, manufacture and delivery.

Our clinical services division is one of the world’s leading providers of innovative clinical supply chain services, with a talented and highly experienced team that can handle every aspect of your supply chain. Our work spans everything from drug development and manufacturing to clinical supplies packaging, labelling, distribution, Qualified Person auditing and comparator sourcing.

membership
Organisation type
Dr Marius Oprean
Business Development Manager 

SiSaf Ltd United Kingdom

SiSaf is a Specialty Biopharmaceutical company with a unique patented next-generation Bio-adoptive silicon technology that can elegantly re-invent and solve even the most complex drug and bio-availability challenges.

Website:
www.sisaf.co.uk
membership
Organisation type
Dr Michael Welsh
Chief Scientific Officer 

Strategy in Life Sciences United Kingdom

Strategy in Life Sciences (SiLS) is a strategy consulting firm focused on the needs of the life sciences sector. We work with organisations to improve their performance, drive high quality decision making and develop winning strategies.

We work on issues from R&D portfolio management to commercial strategy, underpinned by our knowledge of the industry, strategy development and underlying science. Our experience includes working with companies and organisations across the world.

Dr Andrew Bell
LinkedIn logo Managing Director 

Synpromics United Kingdom

Synpromics is a Synthetic Biology company with IP and know-how in the design of Synthetic Promoters.

Our synthetic promoters enable the controlled expression of genes at a specific place, in a specific environment, at a specific time, or in response to a specific biological condition.

We provide solutions to our customers across multiple fields of use. Such as biotherapeutic protein production; targeted gene therapies and DNA vaccines; enhanced functionality of cell therapies; as well as research tools.

Our clients use our promoters in their applications and products. As each promoter is IP protected it allows us to generate revenue through license agreements that provide up-front and milestone payments during our clients product development, and attractive royalties on our clients product sales.

Dr David Venables
LinkedIn logo CEO 
Mr Nick Higgins
Business Development Director 

SYNthesis Research United Kingdom

An Australian headquartered biotechnology company with labs/offices in Melbourne (Australia), Cambridge (UK), San Francisco (USA) and China (Shanghai & Suzhou), SYNthesis Research has established a number of R&D collaborations which have generated novel IP which is now available for partnering. SYNthesis Research's sister company, SYNthesis med chem, is a chemistry-focussed contract research organisation that carries out custom synthesis and medicinal chemistry projects. 

Organisation type
Professor Andrew Wilks
Founder & Chairman 
Mr Simon Bury
Head of Business Development